Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults
JY Song, HJ Cheong, YB Seo, IS Kim… - Clinical and Vaccine …, 2012 - Am Soc Microbiol
Since the first reports of the A/H1N1 virus in April 2009, the pandemic influenza virus spread
globally and circulated for a long time. The primary method for the control of influenza is …
globally and circulated for a long time. The primary method for the control of influenza is …
Point-of-use mixing of influenza H5N1 vaccine and MF59 adjuvant for pandemic vaccination preparedness: antibody responses and safety. A phase 1 clinical trial
MJ Mulligan, DI Bernstein, S Frey… - Open forum …, 2014 - academic.oup.com
Abstract Background. Avian influenza A/H5N1 has threatened human health for nearly 2
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
Long‐term and cross‐reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59‐adjuvanted vaccine versus unadjuvanted vaccine
JY Song, HJ Cheong, JY Noh, YB Seo… - Journal of medical …, 2013 - Wiley Online Library
Elderly people are at great risk for influenza‐related serious complications. However,
influenza vaccine‐induced antibodies are believed to decline more rapidly in the elderly …
influenza vaccine‐induced antibodies are believed to decline more rapidly in the elderly …
Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses
Fifteen meta-analyses have been published between 1995 and 2011 to evaluate the
efficacy/effectiveness and harms of diverse influenza vaccines—seasonal, H5N1 and 2009 …
efficacy/effectiveness and harms of diverse influenza vaccines—seasonal, H5N1 and 2009 …
Safety, tolerability and immunogenicity of an mf59-adjuvanted, cell culture-derived, a/h5n1, subunit influenza virus vaccine: Results from a dose-finding clinical trial in …
P Chanthavanich, E Anderson… - The Pediatric …, 2019 - journals.lww.com
Background: A/H5N1 influenza virus has significant pandemic potential, and vaccination is
the main prophylactic measure. This phase 2, randomized, observer-blind, multicenter study …
the main prophylactic measure. This phase 2, randomized, observer-blind, multicenter study …
Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six-to less than thirty-six-month-old children
SL Block, GM Ruiz-Palacios, ML Guerrero… - The Pediatric …, 2012 - journals.lww.com
Background: The successful vaccination of children 6 to 36 months of age against 2009
A/H1N1 influenza was essential to help reduce the burden of pandemic disease in both the …
A/H1N1 influenza was essential to help reduce the burden of pandemic disease in both the …
Sex Differences in the Immunogenicity and Efficacy of Seasonal Influenza Vaccines: A Meta-analysis of Randomized Controlled Trials
F Tadount, M Kiely, A Assi, E Rafferty… - Open Forum …, 2024 - academic.oup.com
Background Sex impacts individuals' response to vaccination. However, most vaccine
studies do not report these differences disaggregated by sex. The aim of this study was to …
studies do not report these differences disaggregated by sex. The aim of this study was to …
Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted …
HJ Cheong, JY Song, JY Heo, JY Noh… - Clinical and Vaccine …, 2011 - Am Soc Microbiol
Since initial reports in April 2009, the pandemic influenza A (H1N1) virus has spread
globally. Influenza vaccines are the primary method for the control of influenza and its …
globally. Influenza vaccines are the primary method for the control of influenza and its …
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly …
C Hatz, JP Cramer, A Vertruyen, TF Schwarz… - Vaccine, 2012 - Elsevier
BACKGROUND: Modern cell-culture production techniques and the use of adjuvants helps
to ensure that the global demand for pandemic influenza vaccine can be met. This study …
to ensure that the global demand for pandemic influenza vaccine can be met. This study …
Report of the 7th meeting on evaluation of pandemic influenza vaccines in clinical trials, world health organization, Geneva, 17–18 February 2011
MP Girard, JM Katz, Y Pervikov, J Hombach, JS Tam - Vaccine, 2011 - Elsevier
On February 17–18, 2011, the World Health Organization convened the 7th meeting on “The
Evaluation of Pandemic Influenza Vaccines in Clinical Trials” to review the progress made …
Evaluation of Pandemic Influenza Vaccines in Clinical Trials” to review the progress made …